178
Participants
Start Date
September 9, 2014
Primary Completion Date
January 17, 2017
Study Completion Date
January 18, 2017
Lucitanib
Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
Memorial Sloan-Kettering Cancer Center, New York
Weill Cornell Breast Center, New York
Sciode Medical Associates, PLLC, The Bronx
University of Pittsburgh Medical Center, Pittsburgh
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore
Virginia Oncology Associates, Norfolk
Memorial West Cancer Center, Hollywood
University of Miami, Deerfield Beach
Sarah Cannon Cancer Center, Nashville
Vanderbilt Ingram Cancer Center, Nashville
University Hospitals Case Medical Center, Cleveland
Indiana University Simon Cancer Center, Indianapolis
Horizon Oncology Center, Lafayette
Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
University of Chicago Medical Center, Chicago
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
The Center for Cancer and Blood Disorders, Fort Worth
US Oncology, Houston
Texas Oncology - Austin Central, Austin
Arizona Oncology Associates, Sedona
Comprehensive Cancer Centers of Nevada, Las Vegas
University of Southern California, Los Angeles
Cedars-Sinai Medical Center, Los Angeles
University of California, Los Angeles, Los Angeles
Cancer Care Associates Medical Group, Inc., Redondo Beach
Moores UCSD Cancer Center, La Jolla
Saint Jude Heritage Medical Center, Fullerton
Comprehensive Blood and Cancer Center, Bakersfield
Central Coast Medical Oncology Group, Santa Maria
University of California San Francisco, San Francisco
Yale University, New Haven
Dana Farber Cancer Institute, Boston
Cooper University Hospital, Voorhees Township
Lead Sponsor
Clovis Oncology, Inc.
INDUSTRY